No description
-
2016 (v1)PublicationUploaded on: April 14, 2023
-
2016 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2017 (v1)Publication
Background: In the last twenty years routine T CD4+ lymphocyte (CD4) cell count has proved to be a key factor to determine the stage of HIV infection and start or discontinue of prophylaxis for opportunistic infections. However, several studies recently showed that in stable patients on cART a quarterly CD4 cell count monitoring results in...
Uploaded on: April 14, 2023 -
2017 (v1)Publication
Even in the era of highly active antiretroviral therapy (HAART), HIV-infected subjects are at higher risk of complications from vaccine-preventable diseases than those uninfected. Despite the current national and international guidelines strongly recommend that these patients should been immunized, the available data indicate sub-optimal...
Uploaded on: April 14, 2023 -
2017 (v1)Publication
Aims: Despite the remarkable efficacy shown in clinical practice, concerns have been raised about the costs associated with direct antiviral agent (DAA) therapy. This article presents the real-life costs for DAA treatment sustained by the Italian National Health Service in the Liguria Region (Northern Italy). Methods: A retrospective analysis...
Uploaded on: April 14, 2023 -
2017 (v1)Publication
The aim of this retrospective, multicentre, observational study was to assess the durability, safety, immune recovery and effectiveness on viral suppression of antiretroviral therapy (ART) in a maraviroc (MVC)-based cohort. We collected clinical, demographical, immunological and virological parameters of adult HIV patients who were infected by...
Uploaded on: April 14, 2023